Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Mannkind Corporation (NASDAQ: MNKD) | Delayed: 3.10 +0.05 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.05 | 52 Week High | $2.51 | |||
| Open | $3.03 | 52 Week Low | $0.41 | |||
| Day High | $3.11 | P/E | N/A | |||
| Day Low | $3.01 | EPS | $-0.64 | |||
| Volume | 181,419 | |||||
| Mannkind Corporation (NASDAQ: MNKD) | Delayed: 3.10 +0.05 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.05 | 52 Week High | $2.51 | |||
| Open | $3.03 | 52 Week Low | $0.41 | |||
| Day High | $3.11 | P/E | N/A | |||
| Day Low | $3.01 | EPS | $-0.64 | |||
| Volume | 181,419 | |||||
